Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Neohesperidine Dc
2. Neohesperidine Dihydrochalcone
1. 20702-77-6
2. Nhdc
3. Neohesperidin Dc
4. Neohesperidin Dhc
5. Neohesperidine Dihydrochalcone
6. Neohesperidine
7. Nci-c60764
8. Neohesperidin-dihydrochalcone
9. Neosperidin Dihydrochalcone
10. 1-[4-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-2,6-dihydroxyphenyl]-3-(3-hydroxy-4-methoxyphenyl)propan-1-one
11. Neohesperidin Dihydrochalone
12. Chebi:83535
13. 3x476d83qv
14. 1-(4-((2-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl)oxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)propan-1-one
15. 1-propanone, 1-[4-[[2-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl]oxy]-2,6-dihydroxyphenyl]-3-(3-hydroxy-4-methoxyphenyl)-
16. Citrosa
17. Neohesperidine Dc
18. 1-(4-(((2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-(((2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)tetrahydro-2h-pyran-2-yl)oxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)propan-1-one
19. 1-propanone, 1-(4-((2-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl)oxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)-
20. Ccris 4848
21. Einecs 243-978-6
22. Unii-3x476d83qv
23. Neohesperidin Dihydrochalcone (nhdc)
24. Neosperidin-dihydrochalcone
25. Dsstox_cid_5706
26. Dsstox_rid_77887
27. Dsstox_gsid_25706
28. 1-(4-((2-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl)oxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)-
29. 1-propanone, 1-(4-((2-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl)oxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-me
30. 3,5-dihydroxy-4-(3-hydroxy-4-methoxyhydrocinnamoyl)phenyl) 2-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranoside
31. Glucopyranoside, 3,5-dihydroxy-4-(3-hydroxy-4-methoxyhydrocinnamoyl)phenyl 2-o-(6-deoxy-alpha-l-mannopyranosyl)-, Beta-d-
32. Schembl909958
33. Chembl1159645
34. Dtxsid3025706
35. Fema No. 3811
36. Itvgxxminpyuhd-cuvhlrmhsa-
37. Hms3884h13
38. Hy-n0154
39. Zinc4175639
40. Tox21_200303
41. S2331
42. 1-(4-((2-o-[6-deoxy-&alpha
43. Akos015895239
44. Ccg-270237
45. Cs-6419
46. Ncgc00091109-01
47. Ncgc00091109-02
48. Ncgc00091109-04
49. Ncgc00257857-01
50. 1-(4-((2-o-[6-deoxy-alpha-l-mannopyranosyl]-beta-d-glucopyranosyl)oxy)-2,6-dihydroxyphenyl)-3-[3-hydroxy-4-methoxyphenyl]-1-propanone
51. 3,5-dihydroxy-4-[3-(3-hydroxy-4-methoxyphenyl)propanoyl]phenyl 2-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranoside
52. Ac-34860
53. As-15190
54. Glucopyranoside, 3,5-dihydroxy-4-(3-hydroxy-4-methoxyhydrocinnamoyl)phenyl 2-o-(6-deoxy-.alpha.-l-mannopyranosyl)-, .beta.-d-
55. Glucopyranoside, 3,5-dihydroxy-4-(3-hydroxy-4-methoxyhydrocinnamoyl)phenyl-2-o-(6-deoxy-alpha-l-mannopyranosyl)-, Beta-d-
56. Neohesperidin Dihydrochalcone [mi]
57. Neohesperidin Dihydrochalcone, >=96%, Fg
58. Neohesperidin Dihydrochalone [fhfi]
59. Cas-20702-77-6
60. Neohesperidin Dihydrochalcone [inci]
61. Neohesperidine Dihydrochalcone [fcc]
62. N0675
63. Neohesperidin Dihydrochalcone [usp-rs]
64. Neohesperidin Dihydrochalcone, >=95% (hplc)
65. Neohesperidine Dihydrochalcone [usp-rs]
66. Neohesperidin Dihydrochalcone, Analytical Standard
67. 702n776
68. A814825
69. Q424595
70. Sr-01000883756
71. Neohesperidin-dihydrochalcone [ep Monograph]
72. Q-201457
73. Sr-01000883756-1
74. Brd-k61032563-001-02-9
75. Hesperetin Dihydrochalcone-4'-.beta.-neohesperidoside
76. Neohesperidin Dihydrochalcone, European Pharmacopoeia (ep) Reference Standard
77. Neohesperidin Dihydrochalcone, United States Pharmacopeia (usp) Reference Standard
78. 1-(4-((2-o-(6-deoxy-.alpha.-l-mannopyranosyl)-.beta.-d-dihydrochalcone Glucopyranosyl)oxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)propan-1-one
79. 1-(4-((2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-((2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yloxy)tetrahydro-2h-pyran-2-yloxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)propan-1-one
80. 1-[4-[(2s,3r,4r,5r,6s)-4,5-dihydroxy-6-methyl-2-[(2r,3r,4s,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-3-yl]oxy-tetrahydropyran-3-yl]oxy-2,6-dihydroxy-phenyl]-3-(3-hydroxy-4-methoxy-phenyl)propan-1-one
81. 1-[4-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5
82. 1-[4-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-tetrahydropyran-2-yl]oxy-2,6-dihydroxy-phenyl]-3-(3-hydroxy-4-methoxy-phenyl)propan-1-one
83. 1-propanone, 1-(4-((2-o-(6-deoxy-.alpha.-l-mannopyranosyl)-.beta.-d-glucopyranosyl)oxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)-
84. Glucopyranoside, 3,5-dihydroxy-4-(3-hydroxy-4-methoxyhydrocinnamoyl)phenyl 2-o-.alpha.-l-rhamnopyranosyl-
| Molecular Weight | 612.6 g/mol |
|---|---|
| Molecular Formula | C28H36O15 |
| XLogP3 | -0.3 |
| Hydrogen Bond Donor Count | 9 |
| Hydrogen Bond Acceptor Count | 15 |
| Rotatable Bond Count | 10 |
| Exact Mass | 612.20542044 g/mol |
| Monoisotopic Mass | 612.20542044 g/mol |
| Topological Polar Surface Area | 245 Ų |
| Heavy Atom Count | 43 |
| Formal Charge | 0 |
| Complexity | 882 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 10 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Digital Content 
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
27
PharmaCompass offers a list of Neohesperidin Dihydrochalcone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Neohesperidin Dihydrochalcone manufacturer or Neohesperidin Dihydrochalcone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Neohesperidin Dihydrochalcone manufacturer or Neohesperidin Dihydrochalcone supplier.
A Neohesperidin dc manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Neohesperidin dc, including repackagers and relabelers. The FDA regulates Neohesperidin dc manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Neohesperidin dc API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Neohesperidin dc manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Neohesperidin dc supplier is an individual or a company that provides Neohesperidin dc active pharmaceutical ingredient (API) or Neohesperidin dc finished formulations upon request. The Neohesperidin dc suppliers may include Neohesperidin dc API manufacturers, exporters, distributors and traders.
click here to find a list of Neohesperidin dc suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
Neohesperidin dc Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Neohesperidin dc GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Neohesperidin dc GMP manufacturer or Neohesperidin dc GMP API supplier for your needs.
A Neohesperidin dc CoA (Certificate of Analysis) is a formal document that attests to Neohesperidin dc's compliance with Neohesperidin dc specifications and serves as a tool for batch-level quality control.
Neohesperidin dc CoA mostly includes findings from lab analyses of a specific batch. For each Neohesperidin dc CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Neohesperidin dc may be tested according to a variety of international standards, such as European Pharmacopoeia (Neohesperidin dc EP), Neohesperidin dc JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Neohesperidin dc USP).
